What's new? Log in Free sign up

Table search / Recursion Pharmaceuticals, Inc. / "Research and Development"

17 results

Newest first Best match first

RXRX Recursion Pharmaceuticals, Inc.

Quarterly report

Three months ended September 30,	Nine months ended September 30,
2024			2023			2024			2023
Revenue			Operating revenue			$	26,082	$	10,102	$	53,977	$	33,252	Grant revenue	—		431	316	432	Total revenue	26,082		10,533	54,293	33,684	Operating costs and expenses	Cost of revenue			12,079		10,877	32,444	32,706	Research and development	74,600		70,007	216,087	171,744	General and administrative	37,757		29,199	100,998	80,364	Total operating costs and expenses	124,436		110,083	349,529	284,814	Loss from operations	(98,354)		(99,550)	(295,236)	(251,130)	Other income, net	2,679		6,533	9,347	16,060	Loss before income tax benefit	(95,675)		(93,017)	(285,889)	(235,070)	Income tax benefit	(167)		—	1,134	—	Net loss and comprehensive loss	$	(95,842)	$	(93,017)	$	(284,755)	$	(235,070)	Per share data	Net loss per share of Class A, B and Exchangeable common stock, basic and diluted			$	(0.34)	$	(0.43)	$	(1.12)	$	(1.16)	Weighted-average shares (Class A, B and Exchangeable) outstanding, basic and diluted	282,583,048		214,327,186	253,447,099	203,090,637

6 Nov 24

4:18pm

RXRX Recursion Pharmaceuticals, Inc.

Quarterly report

(in thousands, except percentages)	Three months ended September 30,						Change						Nine months ended September 30,			Change
2024			2023			$			%			2024			2023			$			%
Revenue			Operating revenue			$	26,082	$	10,102	$	15,980	>100%	$			53,977	$	33,252	$	20,725	62	%
Grant revenue			—		431	(431)	(100)	%	316			432	(116)	(27)	%
Total revenue			26,082		10,533	15,549	>100%	54,293			33,684	20,609	61	%
Operating costs and expenses			Cost of revenue			12,079		10,877	1,202	11	%	32,444			32,706	(262)	(1)	%
Research and development			74,600		70,007	4,593	7	%	216,087			171,744	44,344	26	%
General and administrative			37,757		29,199	8,558	29	%	100,998			80,364	20,634	26	%
Total operating costs and expenses			124,436		110,083	14,353	13	%	349,529			284,814	64,716	23	%
Loss from operations			(98,354)		(99,550)	1,196	1	%	(295,236)			(251,130)	(44,107)	18	%
Other income, net			2,679		6,533	(3,854)	(59)	%	9,347			16,060	(6,713)	(42)	%
Loss before income tax benefit			(95,675)		(93,017)	(2,658)	3	%	(285,889)			(235,070)	(50,820)	22	%
Income tax benefit			(167)		—	(167)	n/m	1,134			—	1,134	n/m
Net loss			$	(95,842)	$	(93,017)	$	(2,825)	3	%	$			(284,755)	$	(235,070)	$	(49,686)	21	%

6 Nov 24

4:18pm

RXRX Recursion Pharmaceuticals, Inc.

Quarterly report

(in thousands, except percentages)	Three months ended September 30,						Change						Nine months ended September 30,			Change
2024			2023			$			%			2024			2023			$			%
Research and development expense			Platform			$	37,227	$	28,908	$	8,319	29	%	$			95,961	$	68,914	$	27,047	39	%
Discovery			16,584		15,513	1,071	7	%	48,767			45,467	3,300	7	%
Clinical			13,004		18,590	(5,586)	(30)	%	44,310			42,591	1,719	4	%
Stock based compensation			9,457		6,748	2,709	40	%	26,031			14,063	11,968	85	%
Other			(1,672)		248	(1,920)	n/m	1,018			709	309	44	%
Total research and development expense			$	74,600	$	70,007	$	4,593	7	%	$			216,087	$	171,744	$	44,343	26	%

6 Nov 24

4:18pm

RXRX Recursion Pharmaceuticals, Inc.

Quarterly report

Three months ended September 30,	Nine months ended September 30,
(in thousands)			2024			2023			2024			2023
Cost of revenue			$	1,153	$	2,123	$	2,600	$	4,549	Research and development	9,194		6,579	25,141	13,590	General and administrative	7,396		7,640	21,470	17,861	Total	$	17,743	$	16,342	$	49,211	$	36,000

6 Nov 24

4:18pm

RXRX Recursion Pharmaceuticals, Inc.

Quarterly report

Three months ended June 30,	Six months ended June 30,
(in thousands)			2024			2023			2024			2023
Cost of revenue			$	680	$	1,415	$	1,447	$	2,426	Research and development	8,281		4,329	15,947	7,012	General and administrative	6,997		5,643	14,074	10,221	Total	$	15,958	$	11,387	$	31,468	$	19,659

8 Aug 24

8:09am

g9qgfoln9285 5zwfu

Quarterly report

8 Aug 24

8:09am

Quarterly report

8 Aug 24

8:09am

Quarterly report

8 Aug 24

8:09am

r9ar3l4kdhsuvbok8n8q

Quarterly report

9 May 24

4:11pm

Quarterly report

9 May 24

4:11pm

pjjsm6r69 mq0my7

Quarterly report

9 May 24

4:11pm

Quarterly report

9 May 24

4:11pm

xeez80gp0a8rdhgxsg2

29 Feb 24

8:25am

29 Feb 24

8:25am

5qt21yxjk1x bwce5

29 Feb 24

8:25am

29 Feb 24

8:25am

0av7ajot74a kxe

29 Feb 24

8:25am

Prev
1
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.